Skip to main content
IMCR
NASDAQ Life Sciences

Brenetafusp-KIMMTRAK Combo Shows 70% Two-Year Survival in Metastatic Uveal Melanoma

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$29.95
Mkt Cap
$1.505B
52W Low
$27.5
52W High
$40.715
52W Position info
8.9% above low
Off High info
26% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

IMCR is trading near its 52-week low of $27.5 (8.9% above the low).

Summary

Immunocore presented Phase 1/2 data at SITC showing brenetafusp added to KIMMTRAK in first-line metastatic uveal melanoma produced a 70% two-year overall survival rate, with median OS not reached at a median follow-up of 29 months. In 17 evaluable first-line patients the combination delivered a 29% overall response rate, 24.1-month median duration of response, 71% disease control rate and 8.1-month median PFS. The company calls this the first clinical activity shown for a combination of two T cell engagers in a solid tumor, and safety was consistent with the individual agents with no new signals. Immunocore plans a randomized Phase 2/3 trial, DUET-UVEAL, to confirm the combination in this setting. This lands alongside this morning's Q3 update, where KIMMTRAK sales slipped to $102.2M and the pivotal TEBE-AM overall survival readout moved to Q2 2027 — the pipeline data is the offsetting positive. The oral presentation is scheduled for Saturday, November 7 at 3:45 p.m. ET.

At the time of this announcement, IMCR was trading at $29.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $27.50 to $40.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

IMCR - Latest Insights

IMCR
Nov 06, 2026, 9:01 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $27.70
Real-time Price: $26.41 info
Change: -$1.29 (-5%) info
Market Cap: $1.375B info
IMCR
Nov 06, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $27.70
Real-time Price: $26.41 info
Change: -$1.29 (-5%) info
Market Cap: $1.375B info
IMCR
Nov 06, 2026, 9:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $28.40
Real-time Price: $26.41 info
Change: -$1.99 (-7%) info
Market Cap: $1.375B info
IMCR
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $32.60
Real-time Price: $26.41 info
Change: -$6.19 (-19%) info
Market Cap: $1.375B info
IMCR
Aug 06, 2026, 7:05 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $33.20
Real-time Price: $26.41 info
Change: -$6.79 (-20%) info
Market Cap: $1.375B info